358 related articles for article (PubMed ID: 18402717)
41. Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.
Topouzis F; Goldberg I; Bell K; Tatham AJ; Ridolfi A; Hubatsch D; Nicolela M; Denis P; Lerner SF
Eur J Ophthalmol; 2021 Jan; 31(1):103-111. PubMed ID: 31595773
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
Fung AT; Reid SE; Jones MP; Healey PR; McCluskey PJ; Craig JC
Br J Ophthalmol; 2007 Jan; 91(1):62-8. PubMed ID: 16956912
[TBL] [Abstract][Full Text] [Related]
44. Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies.
Realini T; Nguyen QH; Katz G; DuBiner H
Eye (Lond); 2013 Jul; 27(7):841-7. PubMed ID: 23640612
[TBL] [Abstract][Full Text] [Related]
45. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study.
Kobayashi H
J Ocul Pharmacol Ther; 2012 Jun; 28(3):245-50. PubMed ID: 22283238
[TBL] [Abstract][Full Text] [Related]
48. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
49. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma.
Nakamoto K; Yasuda N
J Glaucoma; 2007; 16(4):352-7. PubMed ID: 17570997
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
[TBL] [Abstract][Full Text] [Related]
51. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
52. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
Kóthy P; Holló G
Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
54. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.
Kim CY; Hong S; Seong GJ
J Ocul Pharmacol Ther; 2007 Oct; 23(5):481-6. PubMed ID: 17900227
[TBL] [Abstract][Full Text] [Related]
55. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
[TBL] [Abstract][Full Text] [Related]
57. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
58. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide.
Tsukamoto H; Noma H; Mukai S; Ikeda H; Mishima HK
J Ocul Pharmacol Ther; 2005 Oct; 21(5):395-9. PubMed ID: 16245966
[TBL] [Abstract][Full Text] [Related]
59. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
Greig SL; Deeks ED
Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
[TBL] [Abstract][Full Text] [Related]
60. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
